StockNews.AI
TFC
StockNews.AI
147 days

Truist Securities strengthens its biotech equity research coverage

1. Danielle Brill joins Truist Securities to enhance biotech research coverage. 2. Brill's experience will strengthen advisory for clients navigating biotech investments. 3. Truist continues expanding its research team in high-growth industries. 4. Strategic growth focuses on leveraging new technologies and client services. 5. Truist offers comprehensive capital markets and investment banking services.

7m saved
Insight
Article

FAQ

Why Bullish?

The addition of a skilled professional like Brill may improve research quality, potentially attracting more clients and investments to Truist, positively influencing their stock price.

How important is it?

Brill's appointment strengthens a growing sector like biotech, likely impacting TFC positively as they position for future growth.

Why Long Term?

The structural changes in the team and expanding capabilities will likely enhance Truist's position in the competitive landscape over time, thus benefiting TFC in the longer term.

Related Companies

BMYJNJGILDVRTXAMGN
Danielle Brill joins firm's growing sales, trading, and research team, /PRNewswire/ -- Truist Securities announced today that Danielle Brill has joined the firm as managing director, strengthening its equity research coverage in the biotechnology sector. Brill is the latest addition to Truist Securities, as the firm continues to expand its equity platform to broaden its capabilities in high-growth industries. Danielle Brill "Biotech continues to experience rapid evolution with new treatments and technologies, backed by compelling trial data, growing the market," said Mary Stroth, head of equity sales, trading, and research for Truist Securities. "Danielle's unique insights and analysis will complement our existing team as we advise our institutional clients to navigate factors that impact their investment strategies such as product innovation, loss of exclusivity, and new adjacency use cases." Brill's coverage will complement the research from Truist Securities' existing biotech and specialty pharma analysts, including Asthika Goonewardene, Joon Lee, Srikripa Devarakonda, Nicole Germino, and Les Sulewski. Prior to joining Truist Securities, Brill was a research analyst at Raymond James, where her coverage focused on neurology, hematology, and autoimmune diseases. She also served in research roles at Piper Sandler and Needham & Co. Brill's experience includes time as a clinical pharmacist at Mount Sinai and bench research at Columbia University. Brill earned a Bachelor of Science in human biology from Michigan State University and a Doctorate of Pharmacy from Rutgers University."I am thrilled to join Truist Securities and collaborate with such a talented team," said Brill. "I look forward to bringing my experience in biotech research to help drive continued growth and success at the firm. This is a fantastic opportunity, and I can't wait to make a meaningful impact."Brill is one of the latest additions to Truist Securities' growing equity sales, trading, and research team. Rob Muir joined the firm in early March as managing director and associate director of equity research, bringing more than two decades of experience across a variety of areas including corporate management, financial strategy, valuation, and investor engagement. Muir's background includes roles at Berenberg Bank, Morgan Stanley, and Price Waterhouse Cooper. He most recently served as chief financial officer of Creyon Bio. John McDonald, managing director, Brian Foran, managing director, and David Smith, vice president, joined the firm's equity research team late last year from Autonomous Research. The team recently initiated coverage of large cap banks, regional banks, consumer finance, and trust banks on the Truist Securities platform. Matt Coad, director, also joined the firm's equity research team late last year, focusing coverage on FinTech and payments sub-sectors. Coad's experience includes roles at Autonomous Research, Millennium, and Citi. Managing Directors Paul Durnan (New York sales), David McCormick (New York sales trading), and Charles de Roziere (TMT sales) have strengthened the firm's sales initiatives. Durnan joined from RBC Capital Markets, McCormick from KeyBanc Capital Markets, and de Roziere from Citi. "I'm proud of the exceptional talent we're building to strengthen our equity franchise," said Stroth. "Our focus is on strategic growth to best serve our clients by leveraging new technology and products along with high-touch service to deliver differentiated, data-driven content."About Truist Securities Truist Securities is the full-service corporate and investment banking arm of Truist Financial Corporation (NYSE: TFC). With a rich history extending back more than 125 years, Truist Securities offers a robust capital markets and investment banking platform that includes a comprehensive array of strategic advisory, mergers and acquisition, and capital markets capabilities for corporate and institutional clients, including sales, trading and research services in both fixed income and equity. The firm also provides corporate finance, asset finance, risk management, liquidity, and treasury management solutions to meet clients' full spectrum of financial needs. Headquartered in Atlanta, Truist Securities has offices located across the U.S. Learn more at www.truistsecurities.com.SOURCE Truist Financial Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News